FDG PET-CT对复发鼻咽癌疗效及预后评价研究

doi:10.3760/cma.j.issn.1004-4221.2017.04.004

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (887 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的评价FDG PET-CT显像对复发鼻咽癌疗效监测及其预后评估价值。方法 2008—2013年经病理或影像学确诊的92例复发鼻咽癌,按中国2008鼻咽癌临床分期标准再分期。Ⅰ、Ⅱ、Ⅲ、Ⅳ期分别为8、11、39、34例,其中复发T分期(rT₁)、rT₂、rT₃、rT₄期患者分别为10、11、38、33例。28例同时伴有颈淋巴结复发。所有患者均于疗前行全身或头颈部FDG PET-CT并接受放疗±化疗,分别分析SUV_max及临床各因素与临床预后关系。Kaplan-Meier法计算OS、DFS、LRFS、RRFS、DMFS,Logrank法检验和单因素预后分析,Cox模型多因素预后分析。结果 3年OS、DFS、LRFS、RRFS、DMFS分别为33.6%、32.1%、32.8%、31.8%、33.7%。肿瘤SUV_max中位数为8.35(2.70~21.50)。与3年OS相关最佳截断点SUV_max为7.0,SUV_max≤7.0、>7.0患者3年OS分别为42.0%、28.3%(P=0.019)。单因素分析显示年龄、SUV_max、rN分期与OS相关(P=0.023、0.019、0.002),多因素分析显示SUV_max和rN分期是OS、DFS、DMFS影响因素(HR=1.68,P=0.045和HR=2.23,P=0.003;HR=1.67,P=0.042和HR=2.39,P=0.001;HR=1.77,P=0.025和HR=2.40,P=0.001)。结论 SUV_max可能是影响复发鼻咽癌OS、DFS、DMFS的有效预后因素。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	罗丽
	沈群
	刘峰
	肖锋
	席许平

关键词 ：体层摄影术, X线计算机, 鼻咽肿瘤, 复发, 预后

Abstract：Objective To investigate the value of FDG PET-CT in the outcome assessment and prognostic evaluation for recurrent nasopharyngeal carcinoma (rNPC). Methods From January 2008 to December 2013, 92 rNPC patients were treated in our center, who were histologically or radiologically diagnosed and re-staged according to the 2008 clinical staging system for nasopharyngeal carcinoma in China. The numbers of patients in stage Ⅰ, stage Ⅱ, stage Ⅲ, and stage IV were 8, 11, 39, and 34, respectively. According to the recurrent T stage (rT), the numbers of patients in rT₁, rT₂, rT₃, and rT₄ were 10, 11, 38, and 33, respectively. Twenty-eight patients had recurrence in the neck lymph nodes. All patients underwent pretreatment FDG PET-CT for the whole body or head/neck, and treated by radiotherapy with or without chemotherapy. The relationship of maximum standard uptake value (SUV_max) and clinical factors with clinical outcomes was analyzed. The Kaplan-Meier method was used to calculate overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS). The log-rank test was used for survival difference analysis and univariate prognostic analysis. The Cox model was used for multivariate prognostic analysis. Results The 3-year OS, DFS, LRFS, RRFS, and DMFS were 33.6%, 32.1%, 32.8%, 31.8%, and 33.7%, respectively. The median SUV_max was 8.35(2.7-21.5). The SUV_max of 7.0 was taken as the optimal cut-off value for all patients. Patients with SUV_max≤7.0 had a significantly higher 3-year OS rate than those with SUV_max>7.0(42.0% vs. 28.3%, P=0.019). The univariate analysis revealed that patient age, SUV_max, and rN were significantly associated with OS (P=0.023, 0.019, and 0.002). The multivariate analysis showed that SUV_max and rN were significant influencing factors for OS, DFS, and DMFS (HR=1.68, P=0.045 and HR=2.23, P=0.003;HR=1.67, P=0.042 and HR=2.39, P=0.001;HR=1.77, P=0.025 and HR=2.40, P=0.001). Conclusions SUV_max may be one of the useful prognostic factors for OS, DFS, and DMFS in rNPC patients.

Key words： Tomography,X-ray computed Nasopharyngeal neoplasms,recurrent Prognosis

收稿日期: 2016-09-05

通讯作者: 席许平,Email:xixuping@163.com

引用本文:

罗丽,沈群,刘峰等. FDG PET-CT对复发鼻咽癌疗效及预后评价研究[J]. 中华放射肿瘤学杂志, 2017, 26(4): 384-389.

Luo Li,Shen Qun,Liu Feng et al. Value of FDG PET-CT in outcome assessment and prognostic evaluation for recurrent nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2017, 26(4): 384-389.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2017.04.004 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2017/V26/I4/384

[1] Wei WI,Sham JS.Nasopharyngeal carcinoma. Lancet[J].2005,365(9476):2041-2054.DOI:10.1016/S0140-6736(05)66698-6
[2] Lee AW,Poon YF,Foo W,et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during1976-1985:overall survival and patterns of failure[J].Int J Radiat Oncol Biol Phys,1992,23(2):261-270
[3] Wee J,Tan EH,Tai BC,et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage Ⅲ and Ⅳ nasopharyngeal cancer of the endemic variety[J].J Clin Oncol,2005,23(27):6730-6738.DOI:10.1200/JCO.2005.16.790
[4] Kong L.Salvage intensity-modulated radiation therapy (IMRT) for locally recurrent nasopharyngeal cancer after definitive IMRT:treatment outcomes of a clinically distinct condition in the modern era.(In Press)
[5] Han F,Zhao C,Huang SM,et al. Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity modulated radiotherapy[J].Clin Oncol (R Coll Radiol),2012,24(8):569-576.DOI:10.1016/j.clon.2011.11.010
[6] Qiu S,Lin S,Tham IW,et al. Intensity-modulated radiation therapy in the salvage of locally recurrent nasopharyngeal carcinoma[J].Int J Radiat Oncol Biol Phys,2012,83(2):676-683.DOI:10.1016/j.ijrobp.2011.07.006
[7] Wei J,Pei S,Zhu X.Comparison of (18) F-FDG PET-CT,MRI and SPECT in the diagnosis of local residual/recurrent nasopharyngeal carcinoma:A meta-analysis[J].Oral Oncol,2016,52:11-17.DOI:10.1016/j.oraloncology.2015.10.010
[8] Chan SC,Chang JT,Lin CY,et al. Clinical utility of F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma:predictive role for different survival endpoints and impact on prognostic stratification[J].Nucl Med Commun,2011,32(11):989-996.DOI:10.1097/MNM.0b013e3283495662
[9] Liu WS,Wu MF,Tseng HC,et al. The role of pretreatment FDG-PET in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy[J].Int J Radiat Oncol Biol Phys,2012,82(2):561-566.DOI:10.1016/ j.ijrobp.2010.11.055.
[10] Hung TM,Wang HM,Kang CJ,et al. Pretreatment (18) F-FDG PET standardized uptake value of primary tumor and neck lymph nodes as a predictor of distant metastasis for patients with nasopharyngeal carcinoma[J].Oral　Oncol,2013,49(2):169-174.DOI:10.1016/j.oraloncology.2012.08.011.
[11] Due AK,Vogelius IR,Aznar MC,et al. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline^[18F]-FDG uptake[J].Radiother Oncol,2014,111(3):360-365.DOI:10.1016/j.radonc.2014.06.001.
[12] Yen RF, Hong RL, Tzen KY,et al. Whole-Body FDG PET in Recurrent or Metastatic Nasopharyngeal Carcinoma[J].J Nucl Med,2005,46(5):770-774.
[13] Yi J,Huang X,Gao L,et al. Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma[J].Radiat Oncol,2014,9:56.DOI:10.1186/1748-717X-9-56.
[14] Lin S,Pan J,Han L,et al. Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin[J].Radiother Oncol,2014,110(3):385-389.DOI:10.1016/j.radonc.2014.01.011.
[15] 赵充,肖巍巍,韩非,等.419例鼻咽癌患者调强放疗疗效和影响[J].中华放射肿瘤学杂志,2010,19(3):191-196.DOI:10.3760/cma.j.issn.1004-4221.2010.03.005.
Zhao C,Xiao WW,Han F,et al. Efficacy and effect of intensity modulated radiation therapy in 419 patients with nasopharyngeal carcinoma[J].Chin J Radiat Oncol,2010,19(3):191-196.DOI:10.3760/cma.j.issn.1004-4221.2010.03.005.
[16] Lee AW,Sez WM,Au JS,et alTreatment results for nasopharyngeal carcinoma in the modern era,the Hong kong experience[J].Int J Radiat Oncol Biol Phys,2005,61(4):1107-1116.DOI:10.1016/j.ijrobp.2004.07.702.
[17] Yeh SA,Tang Y,Lui CC,et al. Treatment outcomes and late complications of 849 Patients with nasopharyngeal carcinoma treated with radiotherapy alone[J].Int J Radiat Oncol Biol Phys,2005,62(3):672-679.DOI:10.1016/j.ijrobp.2004.11.002.
[18] Yi JL,Gao L,Huang XD,et alNasopharyngeal carcinoma treated by radical radiotherapy alone:ten-year experience of a single institution[J].Int J Radiat Oncol Biol Phys,2006,65(1):161-168.DOI:10.1016/j.ijrobp.2005.12.003
[19] Chan SC,Chang JT,Wang HM,et al. Prediction for distant failure in patients with stage M₀ nasopharyngeal carcinoma:The role of standardized uptake value[J].Oral Oncol,2009,45(1):52-58.DOI:10.1016/j.oraloncology.2008.03.010.
[20] Han L,Lin SJ,Pan JJ,et al. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy[J].Chin J Cancer,2010,29(2):145-150.
[21] Lee SW,Nam SY,Im KC,et al. Prediction of prognosis using standardized uptake value of 2-^{[(18) F]} fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol[J].2008,87(2):211-216.DOI:10.1016/j.radonc.2008.01.009.
[22] Chan WK,Mak HK,Huang B,et al. Nasopharyngeal carcinoma:relationship between FDG PET-CT maximum standardized uptake value,metabolic tumour volume and total lesion glycolysis and TNM classification. Nucl Med Commun[J].2010,31(3):206-210.DOI:10.1097/MNM.0b013e328333e3ef.
[23] Ma BB,Mo FK,Chan AT,et al. The prognostic significance of tumor vascular invasion and its association with plasma Epstein-Barr virus DNA,tumor volume and metabolic activity in locoregionally advanced nasopharyngeal carcinoma. Oral Oncol[J],2008,44(11):1067-1072.DOI:10.1016/j.oraloncology.2008.02.001.
[24] Wong RJ,Lin DT,Schoder H,et al. Diagnostic and prognostic value of^{[(18) F]}fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol[J].2002,20(20):4199-4208.DOI:10.1200/JCO.2002.02.590.
[25] Chan JY,Chow VL,Mok VW,et al. Prediction of surgical outcome using plasma Epstein-Barr virus dna and (18) F-FDG PET-CT scan in recurrent nasopharyngeal carcinoma. Head neck[J].2012,34(4):541-545.DOI:10.1002/hed.21768.
[26] Shen T,Tang LQ,Luo DH,et al. Different Prognostic Values of Plasma Epstein-Barr Virus DNA and Maximal Standardized Uptake Value of FDG PET-CT for Nasopharyngeal Carcinoma Patients with Recurrence. PLoS ONE[J].10(4):e0122756.DOI:10.1371/journal.pone.0122756.